Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT01741519
• Recruitment Status: Completed
• First Posted: December 5, 2012
• Last Update Posted: April 21, 2015
• Sponsor: AOP Orphan Pharmaceuticals AG
• Information provided by (Responsible Party): AOP Orphan Pharmaceuticals AG

Study Description

Brief Summary:

The study will compare the pharmacokinetics (PK), safety and tolerability of long-term infusion of lyophilized landiolol (LDLL600) against esmolol (Brevibloc) by measurement of blood concentrations of landiolol, esmolol and their metabolites, and by monitoring systemic cardiovascular and local tolerability, blood pressure (BP), ECG including heart rate (HR) and adverse events (AEs).

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: LDLL600; Drug: Brevibloc	Phase 1

Detailed Description:

12 subjects will be administered LDLL600 and Brevibloc in a double-blind, randomized, cross-over setting. PK, systemic cardiovascular and local tolerability and safety of 24-hour long infusions of three dose levels of both Investigational Medicinal Products (IMPs) during each treatment period will be assessed.

Each treatment period will consist of:

Dose level 1 (LOW) for 2 hours (h) Dose level 2 (MEDIUM)for 2 hours Dose level 3 (HIGH)for 2 hours PK and tolerability observation at dose level 3, 2 or 1 will be continued for 18 hours in order to end up with a total infusion period of 24 h Post-infusion follow-up (FU)for 6 hours after infusion termination

The duration of the wash-out period between treatment periods will be at least two days. Each subject, if confirmed eligible, will complete two treatment periods in total.

In case of poor tolerability, alternative dosing schemes will be followed.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 14 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Single Centre Prospective, Randomized, Double Blind, Crossover, Pharmacokinetic, Safety and Tolerability Study to Compare Long-term Infusion Administration of LDLL600 Against Esmolol in Healthy Volunteers.
• Study Start Date: December 2012
• Actual Primary Completion Date: January 2013
• Actual Study Completion Date: January 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: LDLL600; Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.	Drug: LDLL600; Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.; Other Name: Landiolol hydrochloride
Active Comparator: Brevibloc; Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.	Drug: Brevibloc; Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.; Other Name: Esmolol

Outcome Measures

Primary Outcome Measures :

1. PK [ Time Frame: 24 h ]
   PK as measured by Cmax, Tmax, area under curve (AUC), residual area, T1/2, total body clearance (CL) and V
2. Safety [ Time Frame: 24 h ]
   Safety as measured by Adverse events, clinical chemistry, hematology, urinalysis, physical examination, ECG (HR, PQ, QRS, QT and QTc) and BP in mmHG.
3. Local Tolerability [ Time Frame: 24 h ]
   Local tolerability as measured by signs and symptoms of inflammation judged by the clinical investigator on a 6-symptom, 4-point venous score.

Secondary Outcome Measures :

1. Pharmacodynamics (PD) [ Time Frame: 24 h ]
   PD as measured by ECG (HR, PQ, QRS, QT and QTc) and BP in mmHG.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Male and female human subjects, age 18-45 years.
• Body weight of at least 50 kg, maximum of 90 kg. Body-mass index 18.5 to 30.0 kg/m2.
• Caucasian race.
• Subjects without clinically relevant abnormalities as determined by baseline medical history, physical examination, blood pressure, heart rate and ear temperature at screening.
• Subjects without clinically relevant abnormalities as determined by blood count, coagulation tests, biochemistry (except factors for thrombophlebitis), infectious disease screening (HIV, hepatitis B and hepatitis C), urinalysis, ECG, and 2D Echo at screening.
• Subject is willing and able to undergo procedures required by this protocol and gave written informed consent.
• Agreeing to not using any prescription or over the counter medications including vitamins and minerals for 7 days prior to study and during the course of the study (unless prescribed by the principal investigator for treatment of adverse events).
• No history or presence of alcoholism.
• No history of drug abuse (benzodiazepines, barbiturates, cocaine) for the last one month and other illegal drugs for the last 6 months.

Exclusion Criteria:

• Subjects with any condition which in the opinion of the investigator makes the subject unsuitable for inclusion.
• Subjects with history or presence of clinically relevant cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological, psychiatric or skin diseases.
• Subjects with bradycardia (heart rate below 50 bpm), tachycardia (heart rate above 100 bpm), hypotension (systolic blood pressure below 100 mmHg, and/or diastolic blood pressure below 70 mm Hg) at screening, history of clinically relevant arrhythmias.
• Subjects with clinically relevant cardiac supraventricular or ventricular arrhythmias.
• Subjects with atrioventricular block of grade II and III, sick sinus syndrome, sinoatrial block or congestive heart failure.
• Participation in a clinical drug study or bioequivalence study 60 days prior to the present study.
• History of malignancy or other serious diseases.
• Any contraindication to blood sampling.
• History of i.v. drug abuse.
• Subjects with positive HIV tests, HBsAg or Hepatitis C tests or other acute, subacute or chronic infectious disease.
• Known history of hypersensitivity to landiolol, esmolol, or related drugs.
• Refusal to abstain from smoking or consumption of tobacco products 48 hours before drug administration and during the study period.
• Refusal to abstain from alcohol, caffeine, or other xanthines, or grapefruit containing food or drinks for 72 hours before drug administration and during the study period.
• Refusal to abstain from strenuous activities for 7 days before screening and end-of-study examinations, before and during each study period.
• Found positive in breath alcohol test done at the time of screening and on the day of check-in for the study for each period.
• Found positive in urine test for drug abuse done on the day of check-in for the study for each period.
• Subjects with anomalies of the venous and arterial vessels of the forearms or systemic vascular diseases.
• Subjects with small and/or invisible and/or badly visible veins on both forearms.
• Pregnancy and/or breast-feeding.
• History of serious clinical illness that can impact fate of drugs.
• Use of organ toxic drugs within 3 months before the first dose. Any drug with a well-defined potential for toxicity to a major organ or system is to be considered here.
• Systemic multiple dose treatment with drugs altering hepatic metabolism or monoamineoxidase (MAO) inhibitors within 30 days before the first dose.
• Donation of 1) 400 mL of blood or more within 60 days, or 2) more than 150 mL of blood within 30 days, or 3) plasma or platelets within 14 days before the first dose.
• Regular use of medication except hormonal contraceptives or replacement therapy (HC or HRT) taken without significant changes for three months at least.
• Any systemic prescription drug treatment or systemic over-the-counter (OTC) drug treatment within 7 days before the first dose (except HC or HRT).

Contacts and Locations

Locations

Czech Republic

Cepha s.r.o

Pilsen, Czech Republic, 323 00

Sponsors and Collaborators

AOP Orphan Pharmaceuticals AG

Investigators

• Principal Investigator: Ivan Ulc, MD; Cepha s.r.o

More Information

Additional Information:

Sponsor 

• Responsible Party: AOP Orphan Pharmaceuticals AG
• ClinicalTrials.gov Identifier: NCT01741519
• Other Study ID Numbers: AOP LDLL600.101
• First Posted: December 5, 2012
• Last Update Posted: April 21, 2015
• Last Verified: April 2015

Keywords provided by AOP Orphan Pharmaceuticals AG:

PK; PD; landiolol; esmolol; healthy volunteers phase I study

Additional relevant MeSH terms:

Landiolol; Esmolol; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Anti-Arrhythmia Agents